Erythrocyte-driven immunization via biomimicry of their natural antigen-presenting function.
biomimetic
erythrocyte hitchhiking
immunization
spleen targeting
vaccination
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
28 07 2020
28 07 2020
Historique:
pubmed:
16
7
2020
medline:
18
9
2020
entrez:
16
7
2020
Statut:
ppublish
Résumé
Erythrocytes naturally capture certain bacterial pathogens in circulation, kill them through oxidative stress, and present them to the antigen-presenting cells (APCs) in the spleen. By leveraging this innate immune function of erythrocytes, we developed erythrocyte-driven immune targeting (EDIT), which presents nanoparticles from the surface of erythrocytes to the APCs in the spleen. Antigenic nanoparticles were adsorbed on the erythrocyte surface. By engineering the number density of adsorbed nanoparticles, (i.e., the number of nanoparticles loaded per erythrocyte), they were predominantly delivered to the spleen rather than lungs, which is conventionally the target of erythrocyte-mediated delivery systems. Presentation of erythrocyte-delivered nanoparticles to the spleen led to improved antibody response against the antigen, higher central memory T cell response, and lower regulatory T cell response, compared with controls. Enhanced immune response slowed down tumor progression in a prophylaxis model. These findings suggest that EDIT is an effective strategy to enhance systemic immunity.
Identifiants
pubmed: 32665441
pii: 2002880117
doi: 10.1073/pnas.2002880117
pmc: PMC7395435
doi:
Substances chimiques
Antigens
0
Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17727-17736Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL143806
Pays : United States
Déclaration de conflit d'intérêts
Competing interest statement: A.U., Z.Z., and S.M. are inventors on a patent application that covers aspects of the technology described in this manuscript. The patent application is assigned to and managed by Harvard University.
Références
Macromol Biosci. 2012 Dec;12(12):1637-47
pubmed: 23042770
ACS Nano. 2013 Dec 23;7(12):11129-37
pubmed: 24182189
J Immunol. 2018 Sep 1;201(5):1343-1351
pubmed: 30127064
Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):E60-8
pubmed: 23248266
PLoS One. 2015 Mar 09;10(3):e0120826
pubmed: 25751254
Biomaterials. 2017 Apr;123:107-117
pubmed: 28167389
Front Immunol. 2017 Feb 02;8:73
pubmed: 28210260
Drug Des Devel Ther. 2016 Feb 11;10:665-76
pubmed: 26929599
Circulation. 2008 Sep 30;118(14):1442-9
pubmed: 18794394
Cell Physiol Biochem. 2011;28(5):847-56
pubmed: 22178937
Mol Biol Evol. 2002 Mar;19(3):223-9
pubmed: 11861881
Vaccines (Basel). 2015 Apr 16;3(2):320-43
pubmed: 26343190
Pathophysiology. 2016 Jun;23(2):61-6
pubmed: 26971017
Immunol Res. 2018 Apr;66(2):271-280
pubmed: 29508205
Sci Adv. 2019 Nov 13;5(11):eaax9250
pubmed: 31763454
Methods Mol Biol. 2018;1784:259-262
pubmed: 29761405
J Virol. 2005 Apr;79(7):4510-3
pubmed: 15767451
Nat Commun. 2018 Jul 11;9(1):2684
pubmed: 29992966
Adv Drug Deliv Rev. 2019 Mar 15;143:3-21
pubmed: 30639257
J Control Release. 2015 Dec 28;220(Pt A):141-148
pubmed: 26437263
Nature. 2020 Jan;577(7788):95-102
pubmed: 31894150
PLoS One. 2016 Mar 22;11(3):e0152074
pubmed: 27003833
J Immunol. 1987 Dec 1;139(11):3739-47
pubmed: 2960742
Front Immunol. 2018 Nov 20;9:2692
pubmed: 30515169
Sci Rep. 2018 Jan 25;8(1):1615
pubmed: 29371620
Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3157-3162
pubmed: 28270614
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Immunity. 2015 Oct 20;43(4):764-75
pubmed: 26453377
Adv Drug Deliv Rev. 2016 Nov 15;106(Pt A):88-103
pubmed: 26941164
Sci Adv. 2015 Jul 17;1(6):e1500112
pubmed: 26601215
Front Physiol. 2019 Jul 31;10:945
pubmed: 31417415
Arthritis Rheum. 1991 Apr;34(4):442-52
pubmed: 1826424
Front Physiol. 2014 Jan 30;5:9
pubmed: 24523696